Update date
31 Dec 2025
Shareable Research Card
SYRE - Spyre Therapeutics, Inc. Stockholders' Equity Attributable to Parent
This metric view shows SYRE - Spyre Therapeutics, Inc. stockholders' equity attributable to parent history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: Q4 2025
- Latest reported value
- $715,236,000
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 31 Dec 2025
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: Q4 2025.
- Latest reported value on this page: $715,236,000.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Stockholders' Equity Attributable to Parent
Latest reported stockholders' equity attributable to parent: $715,236,000. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
Q4 2025
SEC-backed company facts were refreshed from filings filed on 10 Apr 2026.
Benchmark Context
How Stockholders' Equity Attributable to Parent compares with peers
Spyre Therapeutics, Inc. is outside the visible top 120 companies for stockholders' equity attributable to parent in the current sample.
Compared with
Compared with 120 companies reporting stockholders' equity attributable to parent in USD. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 0x the current sample midpoint. Stockholders' Equity Attributable to Parent is up about 38% versus the comparable prior period.
- Visible rows currently span reported period ends from 30 Sep 2011 to 31 Mar 2026.
- Nearby companies in this sample: BERKSHIRE HATHAWAY INC and Alphabet Inc..
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists and return after a new SEC filing changes the record here.
Financial Metric Page
Spyre Therapeutics, Inc.: Stockholders' Equity Attributable to Parent
Latest period: Q4 2025. Period end: 31 Dec 2025. Units: USD. Frequency: quarterly.
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
Metric Snapshot
- Latest value
- $715,236,000
- Coverage range
- 31 Dec 2013 - 31 Dec 2025
- Fact rows
- 43
What This Metric Tells You
- Shows the reported level of stockholders' equity attributable to parent over 31 Dec 2013 - 31 Dec 2025.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 43 SEC fact rows for this metric and issuer.
How To Read This Chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use quarterly sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
Official SEC Source
Source: SEC Company Facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Compare This Metric Across Companies
Compare latest available Stockholders' Equity Attributable to Parent levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
| Rank | Company | Latest value | Reported period | Next step |
|---|---|---|---|---|
| 1 | BERKSHIRE HATHAWAY INC (brkb) | $717,419,000,000 | Instant - 31 Dec 2025 | Open BERKSHIRE HATHAWAY INC Stockholders' Equity Attributable to Parent |
| 2 | Alphabet Inc. (googl) | $415,265,000,000 | Instant - 31 Dec 2025 | Open Alphabet Inc. Stockholders' Equity Attributable to Parent |
| 3 | AMAZON COM INC (amzn) | $411,065,000,000 | Instant - 31 Dec 2025 | Open AMAZON COM INC Stockholders' Equity Attributable to Parent |
| 4 | MICROSOFT CORP (msft) | $390,875,000,000 | Instant - 31 Dec 2025 | Open MICROSOFT CORP Stockholders' Equity Attributable to Parent |
| 5 | JPMORGAN CHASE & CO (jpm) | $362,438,000,000 | Instant - 31 Dec 2025 | Open JPMORGAN CHASE & CO Stockholders' Equity Attributable to Parent |
| 6 | BANK OF AMERICA CORP /DE/ (bac) | $303,243,000,000 | Instant - 31 Dec 2025 | Open BANK OF AMERICA CORP /DE/ Stockholders' Equity Attributable to Parent |
Metric Details
- Metric
- Stockholders' Equity Attributable to Parent (StockholdersEquity)
- Taxonomy
- us-gaap
- Units tracked
- USD
- Frequency coverage
- quarterly
- History range
- 31 Dec 2013 - 31 Dec 2025
- Facts on this page
- 43
- Description
- Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
- Metric-level SEC endpoint
- Open SEC company concept
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Stockholders' Equity Attributable to Parent, Quarterly (USD)
Stockholders' Equity Attributable to Parent, YoY Quarterly Change (%)
Spyre Therapeutics, Inc. Quarterly Stockholders' Equity Attributable to Parent (USD)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | $715,236,000 | +$197,432,000 | +38% | 31 Dec 2025 | 10-K | 19 Feb 2026 | 2025 | FY |
| Q3 2025 | $455,100,000 | +$127,710,000 | +39% | 30 Sep 2025 | 10-Q | 04 Nov 2025 | 2025 | Q3 |
| Q2 2025 | $455,773,000 | +$81,388,000 | +22% | 30 Jun 2025 | 10-Q | 04 Nov 2025 | 2025 | Q3 |
| Q1 2025 | $482,610,000 | +$330,341,000 | +217% | 31 Mar 2025 | 10-Q | 04 Nov 2025 | 2025 | Q3 |
| Q4 2024 | $517,804,000 | +$333,788,000 | +181% | 31 Dec 2024 | 10-K | 19 Feb 2026 | 2025 | FY |
| Q3 2024 | $327,390,000 | +$572,792,000 | 30 Sep 2024 | 10-Q | 04 Nov 2025 | 2025 | Q3 | |
| Q2 2024 | $374,385,000 | +$581,754,000 | 30 Jun 2024 | 10-Q | 04 Nov 2025 | 2025 | Q3 | |
| Q1 2024 | $152,269,000 | +$118,617,000 | +352% | 31 Mar 2024 | 10-Q | 04 Nov 2025 | 2025 | Q3 |
| Q4 2023 | $184,016,000 | +$133,711,000 | +266% | 31 Dec 2023 | 10-K | 19 Feb 2026 | 2025 | FY |
| Q3 2023 | $245,402,000 | -$312,957,000 | -463% | 30 Sep 2023 | 10-Q/A | 18 Nov 2024 | 2024 | Q3 |
| Q2 2023 | $207,369,000 | -$291,526,000 | -346% | 30 Jun 2023 | 10-Q/A | 18 Nov 2024 | 2024 | Q3 |
| Q1 2023 | $33,652,000 | -$28,005,000 | -45% | 31 Mar 2023 | 10-Q/A | 18 Nov 2024 | 2024 | Q3 |
| Q4 2022 | $50,305,000 | -$33,636,000 | -40% | 31 Dec 2022 | 10-K | 19 Feb 2026 | 2025 | FY |
| Q3 2022 | $67,555,000 | -$34,526,000 | -34% | 30 Sep 2022 | 10-Q | 09 Nov 2023 | 2023 | Q3 |
| Q2 2022 | $84,157,000 | -$34,867,000 | -29% | 30 Jun 2022 | 10-Q | 09 Nov 2023 | 2023 | Q3 |
| Q1 2022 | $61,657,000 | -$62,098,000 | -50% | 31 Mar 2022 | 10-Q | 09 Nov 2023 | 2023 | Q3 |
| Q4 2021 | $83,941,000 | -$55,891,000 | -40% | 31 Dec 2021 | 10-K | 27 Feb 2025 | 2024 | FY |
| Q3 2021 | $102,081,000 | -$34,193,000 | -25% | 30 Sep 2021 | 10-Q | 03 Nov 2022 | 2022 | Q3 |
| Q2 2021 | $119,024,000 | -$33,234,000 | -22% | 30 Jun 2021 | 10-Q | 03 Nov 2022 | 2022 | Q3 |
| Q1 2021 | $123,755,000 | +$80,950,000 | +189% | 31 Mar 2021 | 10-Q | 03 Nov 2022 | 2022 | Q3 |
| Q4 2020 | $139,832,000 | +$79,751,000 | +133% | 31 Dec 2020 | 10-K/A | 18 Nov 2024 | 2023 | FY |
| Q3 2020 | $136,274,000 | +$56,479,000 | +71% | 30 Sep 2020 | 10-Q | 04 Nov 2021 | 2021 | Q3 |
| Q2 2020 | $152,258,000 | +$52,643,000 | +53% | 30 Jun 2020 | 10-Q | 04 Nov 2021 | 2021 | Q3 |
| Q1 2020 | $42,805,000 | -$73,484,000 | -63% | 31 Mar 2020 | 10-Q | 04 Nov 2021 | 2021 | Q3 |
| Q4 2019 | $60,081,000 | -$7,347,000 | -11% | 31 Dec 2019 | 10-K | 02 Mar 2023 | 2022 | FY |
| Q3 2019 | $79,795,000 | +$16,114,000 | +25% | 30 Sep 2019 | 10-Q | 05 Nov 2020 | 2020 | Q3 |
| Q2 2019 | $99,615,000 | +$26,168,000 | +36% | 30 Jun 2019 | 10-Q | 05 Nov 2020 | 2020 | Q3 |
| Q1 2019 | $116,289,000 | +$72,369,000 | +165% | 31 Mar 2019 | 10-Q | 05 Nov 2020 | 2020 | Q3 |
| Q4 2018 | $67,428,000 | +$17,091,000 | +34% | 31 Dec 2018 | 10-K | 08 Mar 2022 | 2021 | FY |
| Q3 2018 | $63,681,000 | +$8,173,000 | +15% | 30 Sep 2018 | 10-Q | 06 Nov 2019 | 2019 | Q3 |
| Q2 2018 | $73,447,000 | +$10,843,000 | +17% | 30 Jun 2018 | 10-Q | 06 Nov 2019 | 2019 | Q3 |
| Q1 2018 | $43,920,000 | -$13,263,000 | -23% | 31 Mar 2018 | 10-Q | 06 Nov 2019 | 2019 | Q3 |
| Q4 2017 | $50,337,000 | -$12,629,000 | -20% | 31 Dec 2017 | 10-K | 18 Mar 2021 | 2020 | FY |
| Q3 2017 | $55,508,000 | -$12,690,000 | -19% | 30 Sep 2017 | 10-Q | 07 Nov 2017 | 2017 | Q3 |
| Q2 2017 | $62,604,000 | -$11,320,000 | -15% | 30 Jun 2017 | 10-Q | 09 Aug 2017 | 2017 | Q2 |
| Q1 2017 | $57,183,000 | +$83,793,000 | 31 Mar 2017 | 10-Q | 09 May 2017 | 2017 | Q1 | |
| Q4 2016 | $62,966,000 | +$85,173,000 | 31 Dec 2016 | 10-K | 24 Feb 2020 | 2019 | FY | |
| Q3 2016 | $68,198,000 | 30 Sep 2016 | 10-Q | 09 Nov 2016 | 2016 | Q3 | ||
| Q2 2016 | $73,924,000 | 30 Jun 2016 | 10-Q | 09 Aug 2016 | 2016 | Q2 | ||
| Q1 2016 | $26,610,000 | 31 Mar 2016 | 10-Q | 19 May 2016 | 2016 | Q1 | ||
| Q4 2015 | $22,207,000 | -$10,734,000 | -94% | 31 Dec 2015 | 10-K | 07 Mar 2019 | 2018 | FY |
| Q4 2014 | $11,473,000 | -$10,200,000 | -801% | 31 Dec 2014 | 10-K | 13 Mar 2018 | 2017 | FY |
| Q4 2013 | $1,273,000 | 31 Dec 2013 | 10-K | 23 Mar 2017 | 2016 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.